# Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

> **NCT04501705** · NA · RECRUITING · sponsor: **Beijing Sanbo Brain Hospital** · enrollment: 29 (estimated)

## Conditions studied

- Recurrent Atypical/malignant Meningioma

## Interventions

- **DRUG:** Apatinib Mesylate

## Key facts

- **NCT ID:** NCT04501705
- **Lead sponsor:** Beijing Sanbo Brain Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-18
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501705, "Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04501705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*